The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment

ConclusionBased on the patterns of birth defects reported, preliminary findings do not suggest a clear signal of human teratogenicity for ribavirin. However, the current sample size is insufficient for definitive conclusions, and ribavirin exposure should be avoided during pregnancy and during the 6 months prior to pregnancy, in accordance with prescribing information.Clinical Trial RegistrationClinicalTrials.gov identifier: NCT00114712.

http://link.springer.com/10.1007/s40264-017-0566-6

Source: Drug Safety - July 8, 2017 Category: Drugs & Pharmacology Source Type: research